skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 

Shares in NMC Health are almost 5% to the good, leading the FTSE100 blue-chip index, after announcing the formation of a joint venture (in which it will have a majority stake and operational control) with Hassana Investment Co. to create new private healthcare platform.

Nothing drastically different to the group’s strategy of incremental and acquisitive growth. Except that this helps further extend a 2016 move into Saudi Arabia (built upon in 2017), a rather significant geography for growth, especially as it modernises under MBS, for a health group focused on the Middle East but predominantly present in the Emirates.

Furthermore, it keeps the shares in the top 5 for 2018 FTSE 100 performance +24%. This is important because its steady incremental growth has helped the shares post impressive historical performance since its March 2012 IPO, with gains of circa 85% in 2015, 2016 and 2017.

With the shares up by 37-50% by this stage of the year in 2016 and 2017, they are a little behind schedule so far this year: +24%. That said, both 2016 and 2017 saw strong FTSE gains (+14% and +7.6%, respectively) and the FTSE is merely +0.4% YTD for 2018.

Even more importantly the shares still grew almost 83% in 2015 (+70% by this stage of the year) even though the FTSE fell by 4.9%.

Even if the shares are off their best levels of 2018 (+32.1% on 25 May), they remain close to the highs.

And there is potential for further incremental growth opportunities, such as that announced today, to help the shares emulate the stellar capital growth of years gone by. No guarantees, but with the shares back firmly in a 2.5yr rising channel, after a brief early June wobble, the odds still looking healthy

Become a better investor with SharePad Designed to give you the confidence to pick your own investments, Sharepad gives you access to a wealth of information on UK, US & European stocks. Find out more

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Mike Van Dulken

Mike van Dulken

Accendo Markets’ Mike van Dulken has worked in the City since 2002, with some of the biggest names in the City. His career kicked off at Jefferies as an equity analyst before a 2007 move to Société Générale saw him help service hedge funds with short-term trade ideas during the financial crisis.

Head of Research at Accendo since 2010, covering shares, indices, commodities and FX, he is regularly quoted in the financial press. Accendo Markets has been voted Best CFD research Service by ADVFN in 2017 and 2018.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.


A date for your diary

On the 21st of October, Stuart Fieldhouse will be joining Sarah Lowther and Mark Watson-Mitchell to discuss which small cap investments they like the look of and, perhaps, which ones they do not. It promises to be a lively and insightful discussion. If you are interested in investing in small cap stocks then this could be a profitable use of your time. We hope you can make it! Sign up now

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Trade Nation
Back To Top